Table 1 Baseline characteristics of the patients within the PAM trial (n = 10)

From: Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study

Age at enrolment (years)

 Median (range)

61.5 (54–71)

Eastern Cooperative Oncology performance status (n (%))

 0

8 (80)

 1

2 (20)

Ethnicity (n (%))

 Caucasian

9 (90)

 Latin American

1 (10)

Histotype (n (%))

 Endometrioid adenocarcinoma

9 (90)

 Dedifferentiated carcinoma

1 (10)

Grade (n (%))

 1

2 (20)

 2

2 (20)

 3

6 (60)

FIGO stage pre-treatment (n (%))a,b

 I

8 (80)

 II

1 (10)

 III

1 (10)

FIGO stage post-treatment (n (%))a,c

 I (IA–IC)

8 (80)

 II (IIA–IIB)

0 (0)

 III (IIIA–IIIC)

2 (20)

Molecular subtype (n (%))

 MMR deficient

10 (100)

 MLH1 and PMS2 deficient

8 (80)

 PMS2 deficient

1 (10)

 MSH6 deficient

1 (10)

Lynch syndrome (n (%))

2 (20)

Myometrial invasion

 <50%

7 (70)

 ≥50%

1 (10)

 Cervical stroma

2 (20)

  1. aThe revised 2009 FIGO staging for endometrial cancer was for staging patients following standard-of-care hysterectomy.
  2. bThe pre-treatment FIGO stage was based on clinical and radiological assessment of the tumour.
  3. cOnly pathological FIGO stage is described since clinical diagnosis was based on pathological classification of the tumour.
Back to article page